Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc (AVIR) Implied Volatility Current
AVIR's 30 day implied volatility is 115.48%, with an IV Rank of 28.97%. This is a low IV Rank versus the past year, meaning Atea Pharmaceuticals Inc options are relatively cheap and currently favor buyers. AVIR's 30 day historical volatility sits at 55.73%, which means implied volatility is running 59.75 points above historical volatility, as of Nov 18, 2026.
Read more
Tracking AVIR implied volatility helps you spot when Atea Pharmaceuticals Inc options are historically cheap or expensive, and where the best trades are hiding. When AVIR IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor AVIR implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking AVIR IV rank helps you see whether AVIR's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection.
Implied Volatility
IV is subdued. Premiums are cheap, favoring buyers.
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →